Literature DB >> 10646853

Identical clonality of sporadic gastrinomas at multiple sites.

S U Goebel1, A O Vortmeyer, Z Zhuang, J Serrano, R T Jensen, I A Lubensky.   

Abstract

Gastrinomas are neuroendocrine neoplasms that occur sporadically and in patients with multiple endocrine neoplasia type 1 (MEN1). In MEN1, multiple gastrinomas have been shown to arise by independent clonal events (Debelenko, et al., Cancer Res., 57: 2238-2243, 1997). The purpose of the present study was to analyze clonality in 20 sporadic gastrinomas from eight patients in whom the tumor was present in at least two separate sites. A combination of methods was used to assess clonality, including MEN1 gene mutation analysis, loss of heterozygosity analysis of the MEN1 locus, and analysis of X-chromosome inactivation at the human androgen receptor locus (human androgen receptor analysis). In three patients, a somantic MEN1 gene mutation was detected in the tumor. Identical mutations were found in other tumors at different sites within the same patients. Human androgen receptor analysis in three informative patients and loss of heterozygosity analysis in five patients revealed identical clonal patterns in the tumors from multiple sites in each patient. We conclude that sporadic gastrinomas at multiple sites are monoclonal and that MEN1 gene alterations in gastrinomas occur before the development of tumor metastases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10646853

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

Review 1.  Potential applications of molecular biology in neuroendocrine tumors.

Authors:  Tommaso Emmer; Marco Volante; Alberto Pagani; Elena Allia; Pellegrino Crafa; Gianni Bussolati
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

2.  Multifocal myxoid liposarcoma--metastasis or second primary tumor?: a molecular biological analysis.

Authors:  Ronald de Vreeze; Daphne de Jong; Petra Nederlof; Henrique J Ruijter; Lucie Boerrigter; Rick Haas; Frits van Coevorden
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.